Suppr超能文献

从 RSK2 氨基端结构域与结合抑制剂的 1.5 Å 晶体结构深入了解黄酮醇糖苷 SL0101 对 p90 核糖体 S6 激酶 (RSK) 的抑制作用。

Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.

机构信息

Department of Molecular Physiology and Biological Physics, University of Virginia, School of Medicine, Charlottesville, VA 22908, USA.

出版信息

Biochemistry. 2012 Aug 21;51(33):6499-510. doi: 10.1021/bi300620c. Epub 2012 Aug 6.

Abstract

The p90 ribosomal S6 family of kinases (RSK) are potential drug targets, due to their involvement in cancer and other pathologies. There are currently only two known selective inhibitors of RSK, but the basis for selectivity is not known. One of these inhibitors is a naturally occurring kaempferol-α-L-diacetylrhamnoside, SL0101. Here, we report the crystal structure of the complex of the N-terminal kinase domain of the RSK2 isoform with SL0101 at 1.5 Å resolution. The refined atomic model reveals unprecedented structural reorganization of the protein moiety, as compared to the nucleotide-bound form. The entire N-lobe, the hinge region, and the αD-helix undergo dramatic conformational changes resulting in a rearrangement of the nucleotide binding site with concomitant formation of a highly hydrophobic pocket spatially suited to accommodate SL0101. These unexpected results will be invaluable in further optimization of the SL0101 scaffold as a promising lead for a novel class of kinase inhibitors.

摘要

p90 核糖体 S6 家族激酶(RSK)是潜在的药物靶点,因为它们参与癌症和其他病理学。目前只有两种已知的 RSK 的选择性抑制剂,但其选择性的基础尚不清楚。其中一种抑制剂是一种天然存在的山柰酚-α-L-二乙酰基鼠李糖苷,SL0101。在这里,我们报道了 RSK2 同工型的 N 端激酶结构域与 SL0101 的复合物的晶体结构,分辨率为 1.5Å。经修正的原子模型揭示了与核苷酸结合形式相比,蛋白质部分的前所未有的结构重组。整个 N lobe、铰链区和αD-螺旋发生剧烈的构象变化,导致核苷酸结合位点重新排列,并伴随形成一个非常疏水的口袋,空间上适合容纳 SL0101。这些出人意料的结果对于进一步优化 SL0101 支架作为一类新型激酶抑制剂的先导化合物将是非常宝贵的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5a4/3462495/4262ded3a165/nihms399326f1.jpg

相似文献

3
Identifying requirements for RSK2 specific inhibitors.鉴定 RSK2 特异性抑制剂的需求。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1798-1809. doi: 10.1080/14756366.2021.1957862.
10
Structural basis for the activity of the RSK-specific inhibitor, SL0101.RSK特异性抑制剂SL0101活性的结构基础。
Bioorg Med Chem. 2007 Jul 15;15(14):5018-34. doi: 10.1016/j.bmc.2007.03.087. Epub 2007 Apr 2.

引用本文的文献

2
RiSKs in Computational Modeling of Isoform-Selective RSK Inhibitors.亚型选择性RSK抑制剂计算建模中的风险
J Chem Inf Model. 2025 Aug 25;65(16):8411-8425. doi: 10.1021/acs.jcim.5c00951. Epub 2025 Aug 12.
6
Therapeutic targeting of p90 ribosomal S6 kinase.p90核糖体S6激酶的治疗靶点
Front Cell Dev Biol. 2023 Dec 19;11:1297292. doi: 10.3389/fcell.2023.1297292. eCollection 2023.
10
Identifying requirements for RSK2 specific inhibitors.鉴定 RSK2 特异性抑制剂的需求。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1798-1809. doi: 10.1080/14756366.2021.1957862.

本文引用的文献

4
Allostery and the Monod-Wyman-Changeux model after 50 years.变构作用和莫诺德-维曼-夏特休斯模型:50 年之后
Annu Rev Biophys. 2012;41:103-33. doi: 10.1146/annurev-biophys-050511-102222. Epub 2012 Jan 6.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验